Answers are grounded in this paper and cite their sources.
Case report reveals photodistributed hyperpigmentation and nail changes in lung cancer, highlighting an uncommon cutaneous toxicity of adagrasib.
Adagrasib is a selective KRAS G12C inhibitor increasingly used in advanced malignancies and is associated with a range of cutaneous adverse effects. However, pigmentary changes remain rarely reported. We report a patient with recurrent KRAS G12C–mutant non–small cell lung cancer who developed photodistributed hyperpigmentation with associated nail matrix changes following adagrasib therapy.
No takes yet. Share an insight, caveat, or question.
Nolan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: